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Biallelic inactivating mutations in DOCK8 cause a combined immunodeficiency
characterized by severe pathogen infections, eczema, allergies, malignancy, and impaired
humoral responses. These clinical features result from functional defects in most
lymphocyte lineages. Thus, DOCK8 plays a key role in immune cell function. Hematopoietic
stem cell transplant (HSCT) is curative for DOCK8 deficiency. While previous reports have
described clinical outcomes for DOCK8 deficiency following HSCT, the effect on
lymphocyte reconstitution and function has not been investigated. Our study determined
whether defects in lymphocyte differentiation and function in DOCK8-deficient patients were
restored following HSCT. DOCK8-deficient T and B lymphocytes exhibited aberrant
activation and effector function in vivo and in vitro. Frequencies of ab T and MAIT cells were
reduced, while gdT cells were increased in DOCK8-deficient patients. HSCT improved
abnormal lymphocyte function in DOCK8-deficient patients. Elevated total and allergen-
specific IgE in DOCK8-deficient patients decreased over time following HSCT. Our results
document the extensive catalog of cellular defects in DOCK8-deficient patients and the
efficacy of HSCT in correcting these defects, concurrent with improvements in clinical
phenotypes. Overall, our findings reveal mechanisms at a functional cellular level for
improvements in clinical features of DOCK8 deficiency after HSCT, identify biomarkers that
correlate with improved clinical outcomes, and inform the general dynamics of immune
reconstitution in patients with monogenic immune disorders following HSCT.
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Biallelic inactivating mutations in DOCK8 cause a combined immunodeficiency characterized 
by severe pathogen infections, eczema, allergies, malignancy, and impaired humoral 
responses. These clinical features result from functional defects in most lymphocyte lineages. 
Thus, DOCK8 plays a key role in immune cell function. Hematopoietic stem cell transplant 
(HSCT) is curative for DOCK8 deficiency. While previous reports have described clinical 
outcomes for DOCK8 deficiency following HSCT, the effect on lymphocyte reconstitution and 
function has not been investigated. Our study determined whether defects in lymphocyte 
differentiation and function in DOCK8-deficient patients were restored following HSCT. 
DOCK8-deficient T and B lymphocytes exhibited aberrant activation and effector function 
in vivo and in vitro. Frequencies of αβ T and MAIT cells were reduced, while γδT cells were 
increased in DOCK8-deficient patients. HSCT improved abnormal lymphocyte function 
in DOCK8-deficient patients. Elevated total and allergen-specific IgE in DOCK8-deficient 
patients decreased over time following HSCT. Our results document the extensive catalog 
of cellular defects in DOCK8-deficient patients and the efficacy of HSCT in correcting these 
defects, concurrent with improvements in clinical phenotypes. Overall, our findings reveal 
mechanisms at a functional cellular level for improvements in clinical features of DOCK8 
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Introduction
Primary immunodeficiencies (PIDs) are rare conditions caused by mutations in a single gene that cripples 
the development and/or function of  immune cells (1, 2). Currently, more than 350 genes have been 
identified that, when mutated, can result in immune dysregulation (1, 3). Although these inborn errors of  
immunity have been typically associated with heightened susceptibility to disease due to recurrent pathogen 
infections, the phenotype of  PIDs is much broader and can include autoimmunity, autoinflammation, 
allergy, and malignancy (1, 4–6). While PIDs due to a specific gene defect are rare, the rapid discovery 
of  the molecular causes of  novel PIDs, the ongoing appreciation of  the diversity of  clinical presentations 
of  these conditions, and the application of  newborn screening across several countries are revealing that 
collectively the incidence of  PIDs is much greater than typically reported (2, 3, 7, 8). For these reasons, it is 
important to understand the biology and pathogenesis of  individual PIDs, and have a thorough knowledge 
of  the optimal treatments and subsequent outcomes for PIDs resulting from mutations in specific pathways.
Severe combined immunodeficiencies (SCID), due to mutations in IL2RG, JAK3, ADA, RAG, or IL7R, 
or combined immunodeficiencies (CIDs), due to mutations in, e.g., DOCK2, STK4, MALT1, CARD11, or 
IKBKB, are usually fatal unless early therapeutic intervention such as hematopoietic stem cell transplant 
(HSCT), gene therapy, or enzyme replacement is applied (2). The first HSCTs for PID were performed in 
1968 (9, 10). While results from these initial transplants for PID were disappointing (9, 10), remarkable 
advances have been made over the past 50 years, such that the overall survival of  SCID/CID patients 
following HSCT can exceed 95% (11–16). However, depending on the age at time of  transplant, incidence 
of  infection, and nature and source of  the donor, mortality after HSCT can remain substantial, with 5- 
to 10-year survival ranging from <40% to ~80% (11–13, 15, 16). Thus, in order to improve therapeutic 
outcomes, it is critical to identify correlates or biomarkers of  successful immune cell reconstitution in PID 
patients following HSCT.
DOCK8 is a guanine nucleotide exchange factor with key roles in regulating cytoskeletal rearrangement, 
cell activation, migration, and survival (17, 18). Despite its broad expression, DOCK8 has a critical and 
nonredundant role in immunity, as revealed by the discovery that biallelic DOCK8 mutations cause a CID 
characterized by recurrent mucocutaneous viral, bacterial, and fungal infections (80%–90% of  cases), 
severe eczema (>95%), allergies (~70%), hyper-IgE (98%), and increased susceptibility to malignancy 
(HPV-induced carcinoma, EBV-associated lymphoma) and autoimmunity (17–22).
Numerous studies have investigated cellular defects in DOCK8 deficiency to understand both the 
nonredundant roles of  DOCK8 in lymphocyte biology and mechanisms of  disease in DOCK8-deficient 
patients. These investigations revealed dysregulated survival, proliferation, differentiation, migration, and 
senescence/exhaustion of  CD4+ and CD8+ T cells (19, 23–27), decreased Treg function (28), NK cell 
cytotoxicity (29, 30) and NKT cell development (31), and reduced B cell activation in vitro and memory B 
cell generation in vivo (32, 33).
Similar to other CIDs, outcomes for DOCK8 deficiency are poor, with >95% mortality by 40 years 
(median survival ~10–20 years), and the incidence of  life-threatening infections and malignancy increases 
every decade (21, 22). Consequently, HSCT is the standard of  care for the life-threatening infections and 
related immune complications associated with DOCK8 deficiency (22). Several studies have examined 
outcomes of  HSCT in DOCK8 deficiency, with generally positive results (~80% survival), but varying 
degrees of  clinical improvement. Eczema, cutaneous viral and bacterial infections, responses to vaccines, 
and levels of  serum IgM, IgG, and IgA all markedly improved after HSCT (34–45). In contrast, allergic 
disease following HSCT is highly variable, resolving (32, 40, 46), improving (32, 34, 35, 37), or persisting 
(32, 41, 47). Clinical improvements in transplanted DOCK8-deficient patients have been associated with 
both mixed (40, 44, 47) and complete (34, 36, 41, 42) donor chimerism.
In this study, we used DOCK8 deficiency as a model to delineate mechanisms underlying disease 
pathogenesis before HSCT and improvement of  clinical features of  PID after HSCT, and identify correlates 
deficiency after HSCT, identify biomarkers that correlate with improved clinical outcomes, and 
inform the general dynamics of immune reconstitution in patients with monogenic immune 
disorders following HSCT.
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of  immune reconstitution and function following HSCT. This allowed us to extensively catalog cellular 
defects due to DOCK8 deficiency and investigate quantitative and qualitative improvement of  these 
defects after HSCT. Cellular improvements correlated with reconstitution of  DOCK8 protein expression 
and clinical outcomes in these patients. To date, this is, to our knowledge, the largest study of  its kind 
and provides insights into the functional changes that may predict successful immune reconstitution and 
guide ongoing treatments and management of  DOCK8-deficient patients following HSCT. Furthermore, 
our study provides proof  of  principle for performing high-dimensional multifunctional cellular analyses 
before and after therapy in other PIDs to understand treatment-induced alterations in cellular behavior and 
clinical outcomes and guide implementation of  optimal treatments for these conditions.
Results
DOCK8 is constitutively expressed by lymphocytes in healthy donors and DOCK8-deficient patients after HSCT. To 
gain insight into the role of  DOCK8 in immune function, we first determined DOCK8 expression in the 
major lymphocyte subsets in PBMCs of  healthy volunteers. DOCK8 was highly and comparably expressed 
in total T cells, CD4+ and CD8+ T cells, B cells, and NK cells (Figure 1A) (48, 49). We also established 
that DOCK8 is constitutively expressed in NKT and mucosal associated invariant T (MAIT) cells (Figure 
1A). Next, we confirmed lack of  expression in patients with DOCK8 mutations and assessed restoration of  
DOCK8 expression following HSCT. Patients studied here exhibited near-undetectable levels of  DOCK8 
protein, with expression in lymphocytes (Figure 1B), CD4+ T cells, CD8+ T cells, and CD20+ B cells 
(Figure 1C) being drastically reduced compared with those from healthy volunteers. Importantly, DOCK8 
expression in these lymphocyte populations from transplanted patients was restored to levels similar to 
those of  lymphocytes from healthy volunteers (Figure 1, B and C).
Clinical characteristics of  DOCK8-deficient patients — impact of  HSCT. We studied an international cohort 
of  DOCK8-deficient patients (Table 1) who had either confirmed biallelic mutations in DOCK8 (n = 18) 
or lacked DOCK8 protein in leukocytes (n = 2). In total, immune cells were examined in 18 DOCK8-
deficient patients after HSCT; matched PBMC samples were available from 7 patients before and after 
HSCT, and 2 patients at 2 or more time points after HSCT. The source of  transplant was haploidentical (n 
= 6), matched unrelated (n = 7), or matched related (n = 6) donors. Consistent with a recent study of  HSCT 
for a large cohort of  DOCK8-deficient patients (32), no correlations were observed between the source of  
the transplant and the overall clinical outcome of  the patients after HSCT (Table 2). All DOCK8-deficient 
patients studied here experienced recurrent viral and bacterial infections (Table 1). Candidiasis was 
reported in 30%, allergies in 80%, and impaired vaccine responses in >90% of  patients (Table 1). Following 
HSCT, infections were reduced, and vaccine responses improved in all DOCK8-deficient patients (Table 2). 
Allergies improved in only 1 of  11 patients tested (Table 2); however, this was an underestimate, as many 
of  the patients did not undergo formal clinical allergy testing after HSCT. Consistent with flow cytometric 
analysis of  DOCK8 expression, which revealed comparable expression in patients after HSCT and healthy 
donors (Figure 1, B and C), donor engraftment following transplant was >90% in all patients (Table 2).
DOCK8-deficient lymphocytes exhibit a unique phenotype typical of  aberrant in vivo differentiation. To elucidate 
the effects of  DOCK8 deficiency on lymphocytes and the impact of  HSCT on these defects, we undertook 
extensive phenotypic analysis. Consistent with previous observations (20, 26), we found reductions in 
proportions of  CD3+ T cells in DOCK8-deficient patients (Figure 2A), largely due to reduced frequencies of  
CD4+ T cells (Figure 2A). Analysis of  T cell subsets confirmed skewing of  DOCK8-deficient CD8+ T cells 
to effector memory (TEM) and effector memory CD45RA
+ (TEMRA) cells at the expense of  naive and central 
memory (TCM) cells (Figure 2B). In contrast, proportions of  naive CD4
+ T cells were comparable to healthy 
controls, while CD4+ TCM cells were decreased and CD4
+ TEM cells were increased (Figure 2C). Tregs were 
proportionally increased in DOCK8-deficient patients compared with controls (data not shown). DOCK8 
deficiency also affected αβ and γδ T cells, with reductions and increases, respectively, in these subsets 
in patients compared with controls, resulting in a skewed αβ/γδ T cell ratio (Figure 2D). Furthermore, 
DOCK8-deficient patients had ~10-fold fewer MAIT cells than healthy controls (Figure 2E); frequencies 
of  NK cells and NK cell subsets were normal (Figure 2F; data not shown; and refs. 20, 29); and NKT cells 
were reduced (Figure 2G) (31). In contrast, proportions of  total (Figure 2A) and naive (Figure 2H) B cells 
were significantly increased in patients compared with healthy donors; however, DOCK8-deficient patients 
had significantly decreased proportions of  total memory B cells (Figure 2H). Interestingly, frequencies of  Ig 
class-switched memory B cells were unaffected by DOCK8 deficiency (Figure 2I).
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Impact of  HSCT on lymphocyte differentiation in vivo in DOCK8-deficient patients. Detailed analysis of  
immune cells in 18 DOCK8-deficient patients 6–43 months after HSCT (mean, 15 months) revealed that 
most of  these defects in lymphocyte differentiation were improved. Specifically, CD3+ T cell proportions 
were significantly increased due to the recovery of  total CD4+ T cells, although they remained reduced 
overall compared with controls (Figure 2A). However, proportions of  CD4+ T cells tended to reached 
normal levels in patients ≥12 months after HSCT (Supplemental Figure 1A; supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.127527DS1). The loss of  naive 
CD8+ T cells and skewing to a CD8+ TEM phenotype in untransplanted patients improved following HSCT 
(Figure 2B). While at the level of  the total cohort, these values were not significantly different compared 
with healthy controls (Figure 2B), they normalized in patients ≥12 months after HSCT (Supplemental 
Figure 1C). CD4+ TCM cells and Tregs were normalized after HSCT, but CD4
+ TEM cells persisted at an 
increased frequency at the expense of  naive CD4+ T cells (Figure 2C and data not shown) until ≥23 months 
after HSCT (Supplemental Figure 1D). Proportions of  αβ and γδ T cells were promptly reestablished by 
Figure 1. DOCK8 is highly expressed in lymphocyte subsets, absent in 
DOCK8-deficient patients and restored following HSCT. (A) PBMCs from 
healthy donors (n = 3) were stained with Abs against CD3, CD4, CD8, 
CD20, CD56, CD161, and TCR Vα24, Vβ11, and Vα7.2. The cells were then 
fixed, permeabilized, and stained with anti-DOCK8 mAb. Expression of 
intracellular DOCK8 in total T cells (CD3+), CD4+ T cells (CD3+CD4+CD8–), 
CD8+ T cells (CD3+CD4–CD8+), B cells (CD20+CD3–), NK cells (CD3–CD56+), 
NKT cells (CD3+TCRVα24+Vβ11+), and MAIT cells (CD3+CD161+TCRVα7.2+) 
was then determined. Data represent the average geometric MFI ± 
SEM of different lymphocyte subsets from 3 unrelated donors labeled 
with anti-DOCK8 mAb less the MFI of cells labeled with isotype control 
mAb. (B and C) PBMCs from healthy donors (n = 20) or DOCK8-deficient 
patients before (n = 4) or following HSCT (pHSCT; n = 15–16) were stained 
with Abs against CD4, CD8, and CD20 before fixing, permeabilization, 
and staining for DOCK8. DOCK8 expression was determined in total 
lymphocytes (B), as well as in CD4+ T cells, CD8+ T cells, and CD20+ B cells 
(C). The histogram in B depicts DOCK8 expression in total lymphocytes 
from 1 representative healthy donor, and lymphocytes from the same 
DOCK8-deficient patient before and after transplant as well as an iso-
type control. The graph in C represents the mean MFI ± SEM of DOCK8 
expression (minus MFI of isotype control mAb). Statistical analysis was 
performed using unpaired t test with Welch’s correction; **P < 0.01, 
****P < 0.001.
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HSCT (Figure 2D and Supplemental Figure 1E); MAIT cells in transplanted DOCK8-deficient patients 
were significantly increased compared with pre-HSCT levels, but remained significantly reduced relative to 
healthy donors in patients irrespective of  time of  analysis after HSCT (Figure 2E and Supplemental Figure 
1F). Strikingly, proportions of  NKT cells remained unchanged in transplanted DOCK8-deficient patients, 
being significantly decreased at all times after HSCT (Figure 2G and Supplemental Figure 1H).
HSCT corrected the increased frequencies of  total (Figure 2A) and naive (Figure 2H) B cells in DOCK8-
deficient patients. Importantly, memory B cells were significantly increased after transplant compared 
Table 1. Clinical details of DOCK8-deficient patients before HSCT
Patient Sex Mutation
Bacterial infections Viral infections
Fungal 
infections
Other infections Allergies Eczema Malignancy
Vaccine 
response
IgE (IU/ml) IV Ig
Skin Other Cutaneous Other
1 F Homozygous del 
exon 37
Yes Sinopulmonary HPV, HSV EBV viremia No Food Severe Vulvar SCC Poor >6000 Yes 
2 M Compound het; 
c.1895G>A, p.W602*; 
c.4540delG, 
p.E1514Kfs8
Yes Sinopulmonary HPV, 
molluscum, 
VZV
EBV viremia No Dust mites Moderate No Variable (poor 
pneumococcal)
4223 No
3 F Compound het; del 
exons 1–13. R249*
Yes Sinopulmonary HPV, molluscum Vaginal 
candidiasis
Food Mild DLBCL Poor 5801 Yes
4 F Homozygous del 
exons 4–13 
Yes Sinopulmonary HPV No Antibiotics Mild No Variable 2 No
5 F Homozygous del 
exons 28–35
Yes Sinopulmonary HSV, zoster, 
HPV
EBV viremia Mucocutaneous 
candidiasis
Food Moderate No Poor 8031 Yes
6 F Compound 
het; c.1266delC 
(p.Try423Thrfs*18), 
del exons 2–47
No Sinopulmonary HPV, molluscum EBV viremia No No Mild (resolved 
pre-HSCT)
No Poor 38.5 Yes
7 M Compound het; 
c.538-18 C>G; del 
exons 14–26 
Yes Sinopulmonary, 
osteomyelitis 
HPV No Food Moderate No Variable (poor 
pneumococcal)
4550 No
8 M Compound 
het; c.1266delC 
(p.Try423Thrfs*18), 
del exons 2–47
No Sinopulmonary HPV, HSV EBV viremia No Food Mild Yes: SCC Poor 118 Yes
9 F Homozygous 
C.2044G>T (E682*)
Yes Sinopulmonary HPV, HSV EBV viremia Yes Food Severe No Variable (poor 
pneumococcal)
6690 No
10 M Compound het; 
c.1153G>T(E385*); 
deletion of DOCK8
Yes Sinopulmonary, 
disseminated; 
Neisseria
HPV, 
molluscum, 
VZV
No No Moderate No Poor 11,279 Yes
11 M Compound het; 
c.3194delC, p.T1065fs
Yes Sinopulmonary Varicella EBV viremia Oral candidiasis Latex Moderate No Variable 679 Yes
12 F Compound het; 
c.1805G>A (p.W602S) 
C. 4540delG 
(p.E1514Kfs*8)
No Sinopulmonary HPV, EBV 
malignancy
EBV viremia No No Mild EBV lymphoma Poor 143 Yes
13 M Compound het: 
C.403IdupT; 
p.Asp1345Argfs*2; 
del exons 1–14
Yes Sinopulmonary HSV EBV viremia No Environmental Mild No Poor 21.5 Yes
14 F Homozygous del 
exons 15–48
No Salmonella, 
severe dental 
caries
Adenovirus, 
molluscum, 
CMV
RSV, rhinovirus, 
adenovirus, 
CMV
Cutaneous 
candidiasis
Cryptosporidium, 
Giardia
Food, drug Mild No Good 
response to 
pneumococcal 
polysaccharide 
vaccine 
Pneumovax 23
~2300 No
15 M Unknown but DOCK8 
protein deficient
No Streptococcus 
pyogenes, 
Haemophilus 
influenzae
HSV, CMV, VZV HHV6, EBV, 
norovirus, 
adenovirus
Candidiasis, 
Aspergillus
Food Yes No Unknown 2586 Yes
16 F Unknown but DOCK8 
protein deficient
No Recurrent lower 
respiratory tract 
infection
HSV (ocular) Chronic ear 
infections
No Food (egg, milk, 
macadamia), 
environmental (house 
dust mites), asthma, 
allergic rhinitis
Yes No Unknown 8100 Yes
17 M c3733_3734delAG 
pR1245Efs*5
No Staphylococcus 
aureus (MRSA); 
recurrent OM
Molluscum CMV viremia No Food, environmental Moderate No Unknown ~1500 Yes
18 F Homozygous 
c.3803delT 
p.Phe1268SERfs*3
Severe S. 
aureus 
pustulosis
Recurrent otitis 
externa with 
pseudomonas
No Adenovirus; 
low-grade CMV 
viremia
No Food, drug, dust mite Severe No Unknown 4868 Yes
19 F A->T; K271* No Pneumonia, 
pneumococcal 
meningitis
Molluscum No No Yes No Poor 
Penumococcal 
Ab responses
10,000 No
20 M Homozygous del 
exons 6–14 included
Unknown Pneumonia, OM Unknown CMV viremia 
(asymptomatic)
Unknown Food allergy (egg, milk, 
arachide), asthma
Yes No Not tested Not done Yes
CMV, cytomegalovirus; DLBCL, diffuse large B cell lymphoma; HSCT, hematopoietic stem cell transplantation; HSV, herpes simplex virus; HHV6, human 
herpes virus 6; IV Ig, intravenous Ig; MRSA, methicillin-resistant Staphylococcus aureus; OM, otitis media; RSV, respiratory syncytial virus; SCC, squamous 
cell carcinoma; VZV, varicella zoster virus.
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Table 2. Clinical details of DOCK8-deficient patients after HSCT
P Age at 
HSCT 
(yr)
Time 
after 
HSCT 
(mo)
Transplant 
type
Transplant 
source
Transplant 
source 
(PBSCs/
BM)
Conditioning 
regimen
Dose of 
conditioning 
regimen
GVHD 
prophy-
laxis
Donor 
chimerism 
at time of 
analysis 
(whole 
blood)
Bacterial 
infections
Viral 
infections
Allergies Eczema Vaccine 
response
IgE (IU/
ml)
IV Ig 
treatment
GVHD Immuno-
supression 
at time of 
analysis
1 19 6 Haploidentical (T 
cell replete with 
posttransplant 
Cy)
Mother BM Bu/Flu Myeloablative TAC/Cy/
MM F
100% (T, B, 
myeloid)
Skin: no
Other: sinus
Skin: no;
Other: no
Yes; has 
not been 
rechallenged
No Unknown 314, 3 
years 
post
No No Tacrolimus
2 20 6 Haploidentical (T 
cell replete with 
posttransplant 
Cy)
Father BM Bu/Flu Myeloablative TAC/Cy/
MMF
100% (T, B, 
myeloid)
Skin: no;
Other: no
Skin: no;
Other: no
Unknown No Normal 389, 3 
years 
post
No Acute; 
grade 3 GI 
Tacrolimus 
and 
low-dose 
prednisone
3 20 6 Haploidentical 
(T cell replete 
with post- 
transplant Cy)
Brother BM Bu/Flu Myeloablative TAC/Cy/
MMF
100% (T, B, 
myeloid)
Skin: no;
Other: no
Skin: no;
Other: no
Yes No Normal 88, 3 
years 
post
No Acute; 
grade I 
skin
Tacrolimus
4 9 12 MUD MUD BM Bu/Flu Myeloablative TAC/MTX 100% T and 
myeloid; B, 
not enough 
cells
Skin: no;
Other: no
Skin: no;
Other: no
Yes: 
medications
No Unknown 64, 3 
years 
post
Yes: for 
cGVHD
Chronic, 
skin and 
myositis
Prednisone, 
MMF, 
tacrolimus, 
rituximab
5 18 12 MRD MRD BM Bu/Flu Myeloablative TAC/MTX 100% (T, B, 
myeloid)
Skin: no;
Other: no
Skin: no;
Other: resolved: 
oral severe HSV
Yes: same No Unknown 1117, 3 
years 
post
No Acute; 
grade II 
skin
Cyclosporine
6 25 6 MUD MUD BM Bu/Flu Myeloablative Cys/MTX 100% (T, B, 
myeloid)
Skin: no:
Other: 
pulmonary 
(bronchiectasis 
persisted) 
Skin: no;
Other: no
Yes: shellfish 
(developed 
post-HSCT) 
No Normal 6.4, 3 
years 
post
No No Cyclosporine
7 19 6 MUD MUD BM Bu/Flu Myeloablative TAC/MTX 100% (T, B, 
myeloid)
Skin: no
Other: sinus
Skin: no;
Other: no
Yes: has 
not been 
rechallenged 
No Normal 453, 3 
years 
post
No No Tacrolimus
8 27 18 MUD MUD PBSCs Bu/Flu Myeloablative TAC/MTX 100% (T, B, 
myeloid)
Skin: no;
Other: no
Skin: no;
Other: no
Yes: has 
not been 
rechallenged
No Unknown 17.4, 3 
years 
post
No No None
9 10 6 MRD Relative BM Bu/Flu Myeloablative TAC 100% B, 
myeloid; 99% 
CD3 T
Skin: no;
Other: no
Skin: no;
Other: HSV 
keratitis vs. 
immune 
reconstitution
Yes: has 
not been 
rechallenged
No Normal 946, 3 
years 
post
No No Tacrolimus
10 23 23 MRD MRD BM Bu/Flu Myeloablative TAC/MTX 100% (T, B, 
myeloid)
Skin: no;
Other: no
Skin: no;
Other: no
No No Normal 644, 3 
years 
post
No Acute; 
grade III 
skin
None
11 7 6 Haploidentical (T 
cell replete with 
posttransplant 
Cy)
Father BM Bu/Flu Myeloablative TAC/Cy/
MMF
100% (T, B, 
myeloid)
Skin: no;
Other: no
Skin: no;
Other: no
Unknown No Normal 15.7, 2 
years 
post
No No Tacrolimus
12 16 6 + 12 MUD MUD PBSCs Bu/Flu Myeloablative TAC 100% (T, B, 
myeloid)
Skin: no
Other: sinus
Skin: no;
Other: no
No No Normal 12.6, 3 
years 
post
No No 6 mo 
cyclosporine 
; 12 mo none
13 7 39 MRD Brother BM Bu/Flu Myeloablative TAC 100% (T, B, 
myeloid)
Skin: no;
Other: no
Skin: no;
Other: no
No Mild Unknown 12.8, 2.5 
years 
post
No Yes None
14 3 23 MUD MUD BM Bu/Flu/ATG Sub-
myeloablative 
MMF/Cys 100% Skin: no;
Other: no
Skin: no;
Other: no
Yes: pistachio, 
tree nut
No Protective 
measles 
and varicella 
IgG after 
vaccination; 
responded to 
Prevanar 13
64, 14 mo 
post
No Chronic None
15 5 40, 50 Haploidentical 
(CD3 TCRαβ/
CD19 depleted)
Father PBSCs Flu/Thio/ATG N/Av MMF/Cys 100% Skin: no;
Other: 
recurrent OM;  
CVL infections: 
Staphylococcus 
aureus, Coryne-
bacterium 
urealyticum
Skin: no;
Other: 
immediate 
post-HSCT CMV 
reactivation, 
low-level 
adenoviremia, 
post-HSCT 
trivirus 
(CMV EBV, 
adenovirus)–
specific CTLs
Yes: dairy, 
egg, nuts
No Tetanus IgG 
0.22 IU/ml, 
diphtheria IgG 
0.37 IU/ml
67 Yes No None
16 N/A N/A N/A N/A N/A N/A N/A Skin: N/A;
Other: N/A
Skin: N/A;
Other: N/A
N/A N/A N/A N/A N/A N/A N/A
17 16 19 Haploidentical 
(CD3 TCRαβ/
CD19 depleted)
Mother PBSCs Treo/Flu/Thio/
ATG
N/Av MMF 89.3% (99% 
T cells)
Skin: MRSA 
lesions; Other: 
Streptococcus 
mitis 
bacteremia
Skin: no;
Other: CMV 
viremia
Yes: skin 
prick positive 
to milk at 2 
years after 
HSCT
No Unknown ND Yes: stopped 
20 mo after 
HSCT
Post-
transplant 
hemolytic 
anemia
None
18 2 6, 9, 12 MUD MUD BM Bu/Flu/ATG Sub-
myeloablative
MMF/Cys 100% Skin: no;
Other: no
Skin: no;
Other: Post-
HSCT CMV 
reactivation and 
CMV retinitis
Unknown No Unknown ND No No None
19 11 11 MRD Sibling BM Treo/Flu/Cam N/Av MMF/Cys 100% Skin: no;
Other: no
Skin: no;
Other: no
Dairy No Normal 89.4 No No None
20 2 12 MRD Sister PBSCs Bu/Flu/Cam Myeloablative MMF/Cys 100% Skin: no;
Other: no
Skin: no;
Other: no
Persistent 
allergies to 
eggs and 
milk
No Yes: T cell 
proliferation 
in response to 
tetanus
4.5 Stop 1 year 
after HSCT
Acute; 
grade II GI
None
There were no fungal infections (data were unavailable for patient 16). ATG, anti-thymocyte globulin; Bu, busulfan; Cam, Campath; CVL, catheter venous line; cGVHD, chronic graft verses host disease; Cy, cyclophosphamide; 
Cys, cyclosporine; CMV, cytomegalovirus; CTL, cytotoxic T lymphocyte; Flu, fludarabine; GI, gastrointestinal; HSCT, hematopoietic stem cell transplantation; HSV, herpes simplex virus; IV Ig, intravenous immunoglobulin; MRSA, 
methicillin-resistant Staphylococcus aureus; MTX, methotrexate; MRD, matched related donor; MUD, matched unrelated donor; MMF, mycophenylate mofetil; N/A, not applicable; N/Av, not available; ND, not done; OM, otitis media; 
TAC, tacrolimus; Thio, thiotepa; Treo, treosulfan; PBSC, peripheral blood stem cell.
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Figure 2. Effect of HSCT on lymphocyte phenotype and differentiation in DOCK8-deficient patients. PBMCs from healthy donors (n = 22–24), 
untransplanted DOCK8-deficient patients (n = 7–9), or DOCK8-deficient patients following HSCT (DOCK8 pHSCT) (n = 18–20) were labeled with mAbs 
against CD3, CD4, CD8, CD20, CD56, CD45RA, CCR7, CD10, CD27, IgM, IgD, TCRαβ, TCRγδ, TCRVα24, TCRVβ11, CD161, and TCR Vα7.2. Proportions of 
(A) CD3+ cells, CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), B cells (CD20+); (B) CD8+ naive (CD45RA+CCR7+), central memory (TCM; CD45RA–CCR7+), 
effector memory (TEM; CD45RA
–CCR7–), and CD45RA+ revertant memory (TEMRA; CD45RA
+CCR7–) cells; (C) CD4+ naive, TCM, and TEM cell subsets; (D) 
αβ and γδ TCR+ T cells; (E) MAIT cells (CD3+TCRVα7.2+CD161+); (F) NK cells (CD3–CD56+); (G) NKT cells (CD3+TCRVα24+ Vβ11+); (H) transitional (Trans; 
CD20+CD10+CD27–), naive (CD20+CD10–CD27–), and memory (CD20+CD10–CD27+) B cell subsets; and (I) Ig class-switched memory (CD20+CD27+ IgD–IgM–) 
B cells were then determined by flow cytometric analysis. Contour plots represent 1 representative normal donor and 1 DOCK8-deficient patient 
before and after HSCT. Data are mean ± SEM. Statistical analysis was performed with GraphPad Prism using unpaired t test with Welch’s correction; 
*P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
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with untransplanted patients, but remained decreased compared with healthy donors (Figure 2H). The 
kinetics of  the concurrent decline in proportions of  transitional and increases in naive and memory B 
cells in transplanted DOCK8-deficient patients (Supplemental Figure 1B) is reminiscent of  the temporal 
reappearance of  these B cell subsets in individuals undergoing HSCT for hematological malignancies (50, 
51). Thus, DOCK8 deficiency affects the generation and differentiation of  a wide range of  lymphocytes 
and HSCT improves most defects, but some improvements are likely to be more time dependent.
Memory T cells in DOCK8-deficient patients exhibit signs of  exhaustion, some of  which persist after HSCT. 
Memory T cells from DOCK8-deficient patients exhibit phenotypic features of  chronic activation or 
exhaustion/senescence (23, 26), which likely impedes their effector function (52, 53). Thus, frequencies 
of  DOCK8-deficient memory CD4+ and CD8+ TEM cells expressing CD57 and PD-1 were significantly 
increased compared with healthy volunteers (Figure 3, A and B). This was coupled with significantly 
decreased expression of  CD127, CD27, and/or CD28 on DOCK8-deficient CD4+ memory and CD8+ 
TEM cells (Figure 3, A and B). Proportions of  patient memory CD4
+ T cells expressing PD-1 and 
CD127 normalized after HSCT, and CD57 was significantly decreased following HSCT but continued 
to exceed that of  healthy volunteers (Figure 3A). CD27 expression on patient memory CD4+ T cells 
improved after HSCT but remained lower than that on memory CD4+ T cells from healthy volunteers 
(Figure 3A). Similar phenotypic changes were observed for CD8+ TEM cells, with HSCT normalizing 
PD-1, CD28, and CD127 and partially correcting CD57 expression (Figure 3B). Taken together, the 
results indicated that HSCT partially restored the exhausted/senescent phenotype of  CD4+ and CD8+ 
T cells in DOCK8-deficient patients.
Defects in proliferation, acquisition of  cytotoxic effector function, and cytokine secretion by CD8+ T cells in 
DOCK8-deficient patients are improved by HSCT. While proliferative, cytoskeletal, and survival defects of  
CD8+ T cells have been proposed to underlie impaired antiviral immunity in DOCK8 deficiency (23, 24), 
the role of  DOCK8 in CD8+ T cell responses has only been assessed in a few patients (19). To investigate 
CD8+ T cell dysfunction due to DOCK8 deficiency, and the effect of  HSCT on these functions, CD8+ T 
cells were labeled with CFSE and cultured for 5 days with anti-CD2/CD3/CD28 mAbs (TAE beads). 
Analysis of  CFSE dilution revealed reduced proliferation of  DOCK8-deficient CD8+ T cells (Figure 4A, 
left panels) (23). While exogenous IL-2 improved proliferation, the extent of  division of  DOCK8-deficient 
CD8+ T cells remained diminished compared with healthy control CD8+ T cells (Figure 4A, right panels).
We next measured acquisition of  a cytotoxic phenotype following in vitro activation. CD107a 
expression, an indicator of  degranulation in CD8+ T cells (54), and granzyme A/B secretion (Figure 4, B 
and C) were significantly decreased for DOCK8-deficient CD8+ T cells compared with healthy volunteers. 
DOCK8-deficient CD8+ T cells also exhibited generalized activation defects, with significantly reduced 
expression of  CD25 and CD95 following in vitro stimulation (Figure 4, D and E). IL-2, IFN-γ, and TNF-α 
secretion by DOCK8-deficient CD8+ T cells was also significantly lower than in healthy controls (Figure 
4F). While exogenous IL-2 increased secretion of  granzymes (Figure 4C), TNF-α and IFN-γ (Figure 4G), 
and CD25 expression (Figure 4D) by CD8+ T cells, the overall response of  IL-2–treated DOCK8-deficient 
CD8+ T cells remained significantly lower than in healthy control CD8+ T cells.
Post-HSCT, CD8+ T cells from DOCK8-deficient patients proliferated as well as those from healthy 
controls even without addition of  IL-2 (Figure 4A). Furthermore, degranulation (Figure 4B), granzyme 
B expression (Figure 4C), CD25 induction (Figure 4D), and IFN-γ, TNF-α, and IL-2 secretion (Figure 
4F) were all restored to normal levels. However, granzyme A secretion (Figure 4C) and CD95 expression 
(Figure 4E) remained significantly decreased. Thus, multiple effector functions of  CD8+ T cells were 
severely compromised in DOCK8-deficient patients, but HSCT largely restored functionality to levels 
similar to those in healthy controls.
Dysregulated cytokine production by CD4+ T cells in DOCK8-deficient patients is normalized by HSCT. Cytokine 
production by in vitro activated memory CD4+ T cells provides information about their differentiation in 
vivo (55). Memory CD4+ T cells from DOCK8-deficient patients showed significantly reduced production 
of  Th1 (IFN-γ/TNF-α) and Th17 (IL-17A/IL-17F) but increased Th2 (IL-4, IL-5, IL-13) cytokines 
compared with healthy controls (Figure 5A and Supplemental Figure 2A) (25, 26).
The defect in generating Th17-type cells in vivo in DOCK8-deficient patients was intrinsic, as revealed 
by impaired induction of  IL-17A/F by DOCK8-deficient naive CD4+ T cells cultured under Th17-
polarizing conditions (Figure 5B). Th2 cytokines (IL-5, IL-13) were normal (Figure 5B). IFN-γ expression 
by DOCK8-deficient naive CD4+ T cells under Th1 conditions was intact (Supplemental Figure 2B), 
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despite reduced secretion (Figure 5B), thus suggesting that an extrinsic defect underlies poor generation of  
Th1 cells in DOCK8-deficient patients in vivo (26).
Consistent with our previous work, both DOCK8-deficient naive (Figure 5B) and memory (Figure 
5A) CD4+ T cells showed defects in proliferation compared with normal healthy controls cells (23, 26). 
Since this could impact cytokine production (56), we investigated IFN-γ expression by memory and Th1-
stimulated naive CD4+ T cells in the context of  cell division. IFN-γ production was decreased across all 
divisions and hence did not result from proliferative defects (Supplemental Figure 2, C and D).
Given the implication of  the Th1/Th2 axis in allergy (57), we further explored Th1 and Th2 cytokine 
production by memory CD4+ T cells at the single-cell level. We used intracellular staining to calculate 
the ratio of  cells producing Th2 (IL-4/IL-13) versus Th1 (IFN-γ/TNF-α) cytokines. DOCK8-deficient 
memory CD4+ T cells showed a significantly increased Th2/Th1 ratio compared with controls (Figure 
5C). In a plot representing each donor and patient showing proportions of  Th2 versus Th1 cells, DOCK8-
deficient memory CD4+ T cells formed a distinct cluster away from control memory cells (Figure 5D). 
Figure 3. DOCK8-deficient memory CD4+ and CD8+ T cells exhibit signs of exhaustion, which decline after HSCT. PBMCs from healthy donors (n = 17–22) 
and DOCK8-deficient patients either before (n = 6–7) or after (n = 16–19) HSCT were labeled with mAbs against CD4, CD8, CD45RA, CCR7, CD127, CD27, CD28, 
PD-1, and CD57. Coexpression of CD127 and PD-1, CD27 and CD57, and CD28 and CD57 by (A) memory CD4+ T cells (CD4+CD8–CD45RA–CCR7+/–) or (B) TEM CD8+ 
T cells (CD8+CD4–CD45RA–CCR7–) was determined. Contour plots are representative of 1 healthy donor and the same DOCK8-deficient patient assessed 
before and after HSCT. The graphs show mean ± SEM. Statistical analysis was performed with Prism using unpaired t test with Welch’s correction; *P < 
0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
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This also revealed that the perturbed Th2/Th1 ratio in each patient resulted from increased Th2 and 
corresponding decreased Th1 cytokine production, further supporting skewed differentiation in vivo.
HSCT greatly improved CD4+ T cell function in vivo in DOCK8-deficient patients. First, proliferation 
of  naive and memory CD4+ T cells from transplanted patients was comparable to controls (Figure 5, A and 
B). Second, Th1 cytokine production (Figure 5A) by memory CD4+ T cells was recovered, while these cells 
produced significantly increased Th17 and decreased Th2 cytokines (Figure 5A and Supplemental Figure 
2A). CD4+CD45RA–CXCR3–CCR6+ Th17 cells (55) also increased after HSCT (before: 4.3% ± 2.1% [n = 
8]; after: 10.4% ± 6.1% [n = 17]). Third, naive CD4+ T cells from DOCK8-deficient patients after HSCT 
produced normal levels of  Th1, Th2, and Th17 cytokines following appropriate polarization (Figure 5B 
and Supplemental Figure 2A). Fourth, the Th2/Th1 cytokine ratio was normalized after HSCT (Figure 
5C). This was due to coincident decreases in Th2 and increases in Th1 cells, as evidenced by a population 
clustered between DOCK8-deficient patients and controls (Figure 5D). Thus, CD4+ T cell differentiation 
defects in DOCK8-deficient patients were restored to normal or near-normal levels by HSCT.
Defective production of  IL-21 by DOCK8-deficient CD4+ T cells. IL-21 potently induces B cell activation, 
differentiation, and Ab production (58). IL-21 production by DOCK8-deficient memory CD4+ T cells 
was significantly decreased compared with healthy donors (Figure 5E). This defect was also cell intrinsic, 
since IL-21 induction in naive DOCK8-deficient CD4+ T cells in vitro was also significantly impaired 
(Figure 5F). Reduced IL-21 production by DOCK8-deficient naive CD4+ T cells was not due to diminished 
proliferation, as fewer IL-21+ cells were detected across all divisions measured compared with those from 
healthy donors (Supplemental Figure 1D). Strikingly, following HSCT, production of  IL-21 (Figure 5E) by 
memory CD4+ T cells in DOCK8-deficient patients was restored, while IL-21 induction in naive CD4+ T 
cells was significantly increased (Figure 5F).
HSCT overcomes the B cell–intrinsic impairment in survival, proliferation, and differentiation due to DOCK8 defi-
ciency. Many DOCK8-deficient patients have impaired antibody responses to vaccines (19, 21, 33) (Table 
1). Dock8 is required in murine B cells to generate germinal centers and long-lived humoral immunity (59), 
and studies of  DOCK8-deficient humans reported reductions in memory B cells (33) and compromised in 
vitro activation of  naive B cells and identified DOCK8 as an adaptor for TLR signaling (33, 60, 61). To 
extend these findings, we examined the impact of  DOCK8 deficiency on naive B cell function by assessing Ig 
secretion in vitro. When stimulated with mimics of  T cell help (CD40L/IL-21), TLR ligands (CpG), and BCR 
agonists, naive B cells from healthy volunteers secreted IgM (Figure 6A). CD40L/IL-21 or CD40L/CpG/
BCR stimulation also induced switching to IgG and IgA (Figure 6A), with CD40L/CpG/BCR being less 
effective than CD40L/IL-21 (Figure 6A). DOCK8-deficient naive B cells secreted significantly lower levels 
of  IgM, with a trend toward decreased IgG and IgA under most in vitro conditions (Figure 6A). DOCK8-
deficient naive B cells also exhibited significantly compromised survival and proliferation in vitro compared 
with control naive B cells (Figure 6, B and C). These data demonstrate that DOCK8-deficient B cells are 
defective in responding not only to TLR- (33, 61) and BCR-mediated (60) signals, but also those delivered 
via CD40 and cytokines. Survival, proliferation, and secretion of  IgM and IgG by naive B cells isolated 
from transplanted DOCK8-deficient patients were largely restored (Figure 6, B and C). In contrast, IgA 
secretion by naive B cells from transplanted patients remained significantly lower than controls (Figure 6D). 
These findings reveal that DOCK8 deficiency intrinsically impairs naive B cell survival, proliferation, and 
differentiation, establishing that DOCK8-dependent signals are elicited in B cells downstream of numerous 
stimulatory receptors. However, these key functions are almost completely regained following HSCT, thus 
explaining improved humoral immune responses in DOCK8 deficiency after HSCT (Table 2).
Elevated serum IgE and allergen-specific IgE levels decrease in a time-dependent manner following HSCT 
of  DOCK8-deficient patients. Most DOCK8-deficient patients have extremely high levels of  total and 
Figure 4. HSCT overcomes CD8+ T cell functional defects due to DOCK8 deficiency. CD8+ T cells were sorted from the peripheral blood of healthy donors (n 
= 18–26), untransplanted DOCK8-deficient patients (n = 2–7), and DOCK8-deficient patients following HSCT (DOCK8 pHSCT) (n = 13–18); labeled with CFSE; 
and then cultured with TAE (anti-CD2/CD3/CD28) beads in the absence or presence of IL-2. After 5 days, culture supernatants were collected, and cells were 
harvested and then restimulated with PMA/ionomycin for 6 hours, with brefeldin A, monensin, and anti-CD107a mAb being added after 1 hour. (A) The 
frequency of cells in each division was determined by dilution of CFSE. (B) Expression of CD107a and (C) secretion of granzyme A and granzyme B were deter-
mined by flow cytometry and cytometric bead arrays, respectively. (D) Surface expression of CD25 and (E) CD95 was determined by flow cytometry. (F and 
G) Secretion of IFN-γ, TNF-α, and IL-2 was determined by cytometric bead arrays. Histograms in A, B, D, and E are representative of one healthy donor and 
one paired DOCK8-defcient patient before and after HSCT. Data represent the mean ± SEM. Statistics performed using Prism unpaired t test with Welch’s 
correction *P < 0.05, **P < 0.01, ***P < 0.005.
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allergen-specific IgE, consistent with severe allergies (19, 20, 26). Indeed, total and food allergen–specific 
IgE levels were increased 50- to 1000-fold in the DOCK8-deficient patients studied here compared with 
healthy controls (Table 1 and Figure 7A). However, dust mite–specific IgE was normal or moderately 
increased in DOCK8-deficiency (Figure 7A). After HSCT, all patients showed decreased total and food 
allergen–specific IgE compared with pre-HSCT levels (Tables 1 and 2 and Figure 7A). One patient 
Figure 5. Dysregulated cytokine production by 
DOCK8-deficient CD4+ T cells is greatly improved 
following HSCT. Naive and memory CD4+ T cells were 
sort-purified from the peripheral blood of healthy 
donors (n = 7–25), untransplanted DOCK8-deficient 
patients (n = 2–7), and DOCK8-deficient patients 
following HSCT (DOCK8 pHSCT) (n = 6–18). The cells 
were labeled with CFSE and then cultured under Th0 
conditions (TAE beads; naive and memory), or Th1- 
(+IL-12), Th2- (+ IL-4), or Th17-polarizing (IL-1β, IL-6, 
IL-21, IL-23, TGF-β, prostaglandin E2) conditions (naive 
only) for 5 days. (A and B) Cells and culture superna-
tants were harvested to assess proliferation of (CFSE 
dilution) and cytokine secretion of (A) Th1 cytokines 
(IFN-γ/TNF-α), Th2 cytokines (IL-4/IL-5/IL-13), or Th17 
cytokines (IL-17A/IL-17F) by memory CD4+ T cells, and 
of (B) of Th1 cytokines (IFN-γ/TNF-α), Th2 cytokines 
(IL-5/IL-13), or Th17 cytokines (IL-17A/IL-17F) naive CD4+ 
T cells. (C and D) Cells were restimulated with PMA/
ionomycin before permeabilization and intracellular 
staining to determine proportions of cells expressing 
Th1 (IFN-γ, TNF-α) and Th2 (IL-4, IL-13) cytokines. Data 
are presented as (C) the ratio of cells expressing Th2 
versus Th1 cytokines and (D) the combined percentage 
of cells from individual donors and patients expressing 
Th1 (i.e., %IFN-γ+/TNF-α+/IFN-γ+TNF-α+ cells) versus 
Th2 (i.e., %IL-4+/IL-13+/IL-4+IL-13+ cells) cytokines. (E 
and F) Intracellular expression of IL-21 by memory CD4+ 
T cells (E) and naive CD4+ T cells cultured under Th0- 
or Th1-polarizing conditions (F) cells was measured. 
Graphs show mean ± SEM. Statistical performed with 
Prism using unpaired t test with Welch’s correction; *P 
< 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
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Figure 6. B cell functional defects due to DOCK8 defi-
ciency are improved following HSCT. (A) Naive B cells 
were sort-purified from healthy donors and DOCK8-defi-
cient patients (n = 7) and then cultured with CD40L/IL-21, 
CD40L/CpG, CpG/BCR agonist (Staphylococcus aureus 
Cowan I), or CD40L/CpG/BCR. After 11 days, culture 
supernatants were harvested and levels of secreted IgM, 
IgG, and IgA then determined. Data represent mean ± 
SEM. (B–D) Naive B cells were sort-purified from healthy 
donors (n = 18–23), untransplanted DOCK8-deficient 
patients (n = 5–7), and DOCK8-deficient patients follow-
ing HSCT (DOCK8 pHSCT) (n = 12–15); labeled with CFSE; 
and then cultured with combinations of CD40L, IL-21, 
CpG, and BCR stimulus for 5 days. After this time, cells 
and culture supernatants were harvested. (B) Cell number 
was determined using Calibrite beads. (C) Frequency of 
cells in each division was determined by CFSE dilution. 
Histogram plots show CFSE dilution from 1 representa-
tive healthy donor and 1 paired DOCK8-deficient patient 
before and after HSCT. (D) Secretion of IgM, IgG, and IgA 
was determined by ELISAs. Data in each graph represent 
mean ± SEM. Statistical analysis was performed with 
Prism using unpaired t test with Welch’s correction; *P < 
0.05, **P < 0.01, ****P < 0.001.
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had moderately positive dust mite allergen–specific IgE levels before HSCT, which was also reduced 
following HSCT (Figure 7A).
HSCT has been reported to have mixed outcomes on allergy in DOCK8 deficiency (32, 46, 47). We 
also noted variability in reductions in total and allergen-specific IgE, ranging from 2- to >1000-fold (Figure 
7A). To investigate this further, we expressed IgE levels following HSCT as a percentage of  pre-transplant 
levels for each patient and as a function of  time after HSCT. For this, we could also study 2 patients 
longitudinally. This revealed that the magnitude of  the reduction in total and specific IgE levels in DOCK8-
deficient patients was time dependent after transplant (Figure 7B). In general, food-specific IgE levels 
declined at a slower rate than total IgE levels (Figure 7B). Hence, elevated IgE levels in DOCK8-deficient 
patients were decreased with HSCT and tended to normalize over time.
Impact of  HSCT on lymphocyte reconstitution in other PID patients. It was possible that some of  the 
impairments in lymphocyte differentiation in transplanted DOCK8-deficient patients were unique to 
DOCK8 deficiency or a general consequence of  HSCT in PID. To differentiate between these possibilities, 
we examined lymphocytes in 8 additional PID patients who underwent HSCT due to loss-of-function 
mutations in UNC13D (n = 2), STK4 (n = 2), CYBB (n = 2), CD40LG (n = 1), or SH2D1A (n = 1) (Table 3) 
(62–64). Time after HSCT ranged from 5 to 84 (mean 44.5) months (Table 3). Proportions of  CD3+, CD4+, 
and CD8+ T cells in these transplanted PID patients were comparable to healthy controls, while B cells 
were increased (Figure 8A). Memory B cells were reduced following HSCT (Figure 8B), but differentiation 
of  CD4+ and CD8+ T cells was normal (Figure 8, C and D). Expression of  exhaustion/senescence markers 
on CD4+ memory T cells in these transplanted PID patients was comparable to that on CD4+ memory T 
cells from healthy donors (Figure 8E); however, patient CD8+ TEM cells showed decreased expression of  
CD28 and CD127 relative to controls (Figure 8F). Interestingly, these PID patients exhibited decreased 
frequencies of  MAIT (Figure 8G) and NKT cells (Figure 8H) after HSCT.
We investigated STK4-deficient patients in more detail, as STK4 deficiency shares clinical features 
with DOCK8 deficiency, including susceptibility to viral infections, elevated serum IgE, naive T cell 
Figure 7. Elevated total and allergen-specific serum IgE levels decrease in a time-dependent manner in DOCK8-deficient patients following HSCT. (A) 
Serum from healthy donors (n = 5) and DOCK8-deficient patients (n = 4–18) collected before and after HSCT was analyzed for concentrations of total IgE 
and IgE specific for staple foods and dust mites. (B) Data in A expressed as a percentage of pre-transplant levels of total and allergen-specific IgE for each 
patient and plotted against the time after HSCT. Points joined by a line are from the same patient (patients 16 and 18 in Table 1) assayed at different times 
after HSCT. Dotted line indicates average of healthy control values as percentage of average of patient pre-transplant values.
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Figure 8. Lymphocyte phenotype and differentiation in PID patients pHSCT. PBMCs from healthy donors (n = 5–7) or patients with mutations in 
UNC13D (n = 2), STK4 (n = 2), CYBB (n = 2), CD40LG (n = 1), or SH2D1A (n = 1) who had previously undergone HSCT (PID pHSCT) (n = 6–8) were labeled 
with mAbs against CD3, CD4, CD8, CD20, CD45RA, CCR7, CD10, CD27, CD28, CD57, CD127, PD-1, TCRVα24, TCRVβ11, CD161 and TCR Vα7.2 (see Figure 
1 legend). Proportions of (A) CD3+ cells, CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), B cells (CD20+); (B) transitional, naive and memory B cell 
subsets; (C) CD4+ naive, TCM, and TEM cell subsets; (D) CD8+ naive, TCM, TEM, and TEMRA cell subsets; (E) CD4+ memory and (F) CD8+ TEM cells expressing 
CD57, PD-1, CD27, CD28, and CD127; (G) MAIT cells; and (H) NKT cells were then determined by flow cytometric analysis. (I) Naive B cells were sorted 
from healthy donors (n = 3), STK4-deficient patients (n = 1), or STK4-deficient patients following HSCT (STK4 pHSCT) (n = 2) and cultured with CD40L 
+ IL-21 for 5 days. After this time, culture supernatants were harvested, and secretion of IgM, IgG and IgA was determined by ELISAs. Points joined 
by lines represent data from the same patient before and after HSCT. Data are mean ± SEM. Statistical analysis was performed with Prism using 
unpaired t test; *P < 0.05, **P < 0.01, ***P < 0.005.
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lymphopenia, and reduced memory B cells (18, 62). Naive B cells from 
STK4-deficient patients exhibit impaired production of  IgM, IgG, and IgA 
following in vitro stimulation with CD40L/IL-21 (62) (Figure 8I). However, Ig 
production by naive B cells isolated from these patients and activated in vitro 
was normalized following HSCT (Figure 8I). Thus, analysis of  patients with 
DOCK8 deficiency or other inborn errors of  immunity allowed us to identify 
specific and general outcomes for reconstitution of  lymphocyte development, 
differentiation, and function following HSCT.
Discussion
The study of  cellular defects due to DOCK8 deficiency is essential to reveal 
mechanisms underlying the constellation of  clinical features in these patients. 
Previous studies showed that DOCK8 deficiency compromises memory 
B cell generation, NK cell cytotoxicity, NKT cell development, CD8+ T cell 
differentiation, CD4+ T cell cytokine production, and Treg function (23, 25–31, 
33). We have confirmed and substantially extended these findings to produce 
a comprehensive catalog of  phenotypic and functional defects in DOCK8-
deficient lymphocytes, including impaired CD8+ T cell cytotoxicity, reduced B 
cell survival and proliferation, poor induction of  Tfh-type cells, and defective 
generation of  MAIT cells. Collectively, these defects explain the poor control of  
pathogen infections, impaired humoral immunity, and severe atopic disease in 
individuals with DOCK8 mutations.
HSCT is the only treatment capable of  curing DOCK8 deficiency. Cellular 
mechanisms underlying clinical improvements after HSCT have not previously 
been established. DOCK8-deficient patients assessed in our study reported 
poor vaccine responses prior to HSCT (Table 1) but normal responses after 
HSCT (Table 2). This correlated with functional improvements in naive B 
cell survival, proliferation, and differentiation in vitro and a significant, albeit 
incomplete, increase in memory B cell formation in vivo. CD19 expression is 
reduced on DOCK8-deficient human B cells, and it has been proposed that this 
contributes to poor B cell responses in vivo (60). We confirmed this reduction 
in CD19 expression and noted that HSCT increased CD19 on patient B cells 
(data not shown); this may also facilitate improved B cell behavior in DOCK8-
deficient patients after HSCT. Due to the kinetics of  memory B cell generation 
after HSCT (50, 51) and the increases in serum IgG and IgA during the first 
years of  life (65), reconstitution of  the memory compartment in DOCK8-
deficient patients is expected to increase with time following HSCT. Indeed, 
we observed that a normal frequency of  memory B cells was achieved in 
patients who were ≥23 months after transplant (Supplemental Figure 2B). 
This was also observed for the non-DOCK8 PID patients examined, inasmuch 
as the patients who were tested ≥60 months after HSCT had the highest 
proportions of  memory B cells in peripheral blood (Figure 8B). It is likely that 
the increased ability of  naive and memory CD4+ T cells from HSCT DOCK8-
deficient patients to produce IL-21 would also contribute to improved B cell 
function, given the potency of  IL-21 in inducing human B cell proliferation 
and differentiation into plasma cells (PCs) (58).
The prevalence and severity of  infections in DOCK8-deficient patients before 
transplant were dramatically reduced following HSCT. Many cellular changes 
are likely responsible for improved host defense, including increased frequencies, 
proliferation, and normalized differentiation of  CD4+ T cells. Increased Th1 
and Th17 cytokines would contribute to effective control of  bacterial, viral, 
and fungal infections in transplanted DOCK8-deficient patients. Furthermore, 
restored differentiation and production of  cytokines and cytolytic mediators 
by DOCK8-deficient CD8+ T cells would reduce viral infections after HSCT. Ta
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The mild recovery of  MAIT cells may also be important in host defense in DOCK8 deficiency after HSCT 
(66). Last, resolution of  severe skin inflammation after HSCT could in part be attributed to decreased Th2 
skewing and concordant reductions in total and allergen-specific IgE. IL-21R–deficient mice and humans 
have increased serum IgE (67, 68), and administering IL-21 to Dock8-deficient mice alleviates disease in an 
allergic asthma model (69). Thus, increased IL-21 production by CD4+ T cells in transplanted DOCK8-
deficient patients may not only contribute to improved humoral immunity, but also mediate improvements in 
allergy and reductions in serum IgE. Similarly, since CpG activation suppresses IgE production by CD40L/
IL-4–stimulated human naive B cells (61), restored TLR signaling in B cells after HSCT may also contribute 
to reductions in serum IgE in DOCK8-deficient patients.
Malignancies occur in 10%–15% of  DOCK8-deficient patients. Indeed, ~30% of  patients studied here 
reported malignancies prior to HSCT. Incidence of  malignancies in transplanted patients has not been 
described, likely due to insufficient follow-up times. However, the lack of  malignancy among patients in 
our study and other reports (37, 43, 44) suggests that by restoring CD8+ T cell cytotoxic function, HSCT 
also protects against tumorigenesis in DOCK8 deficiency.
Despite effective control of  infections due to improved cellular function in patients after HSCT, 
memory T cells still exhibited modest signs of  chronic activation/exhaustion. This could reflect 
reactivation of  latent viruses. Indeed, EBV reactivation occurs in ~20% of  HSCT patients (70), while 
CMV reactivation following HSCT is associated with exhausted CD8+ T cells compared with patients 
who did not experience viral reactivation after HSCT (71). Interestingly, 2 patients we studied had 
CMV reactivation after HSCT (DOCK8 patients 15 and 18), but no further complication. Additionally, 
exhaustion of  CD4+ and CD8+ memory T cells in DOCK8-deficient patients was reduced ≥12 months 
after HSCT (Supplemental Figure 1, I and J), suggesting that the effects of  viral reactivation are short 
lived due to functional reconstitution of  immune cells.
HSCT has been reported to have variable outcomes for allergic disease in DOCK8-deficient patients. 
Thus, it has been reported that HSCT led to resolution (34, 37, 72), improvement (35, 44), or persistence (41, 
47, 73) of  allergies in these patients. However, a recent study of  56 transplanted DOCK8-deficient patients 
found that food allergies resolved or improved in 61% of  cases (32). Furthermore, as a substantial proportion 
of  this cohort avoided allergen exposure after HSCT, the actual level of  allergy improvement was nearly 
80% (34 of  43 patients) (32), suggesting that HSCT positively impacts allergic disease in DOCK8 deficiency. 
Our findings of  decreased production of  Th2 cytokines by memory CD4+ T cells and corresponding 
reductions in serum levels of  allergen-specific IgE in DOCK8-deficient patients with time are consistent 
with decreased allergic disease in cohorts of  transplanted DOCK8-deficient patients. Furthermore, the 
kinetics of  reduction in total and allergen-specific IgE could explain conflicting results regarding the impact 
of  HSCT on allergic disease in DOCK8 deficiency. Long-lived host PCs in bone marrow may produce IgE 
in DOCK8-deficient patients after HSCT (40, 44, 47). They may survive conditioning but be displaced from 
survival niches by newly generated PCs, resulting in apoptosis (74). Hence, the time-dependent decrease 
in allergen-specific IgE in transplanted patients could result from the gradual turnover of  IgE+ PCs by 
the reconstituted donor immune system. Continued longitudinal assessment of  transplanted patients will 
establish the long-term efficacy of  HSCT on allergic disease in DOCK8-deficient patients.
Successful immune reconstitution following HSCT often depends on high donor chimerism (75). Previous 
reports detected >95% chimerism in CD4+ and CD8+ T cells (34, 36, 40, 41), but varying (0%–100%) levels 
for B cells (38, 41), in HSCT DOCK8-deficient patients. Despite this, DOCK8-deficient patients with mixed B 
cell chimerism showed improvements comparable to patients with complete donor chimerism (40), indicating 
that high donor chimerism is not the sole determinant of  restored immune function following HSCT of these 
patients. Interestingly, some DOCK8-deficient patients undergo somatic reversion and reexpress functional 
DOCK8 protein in leukocytes (48). DOCK8 was expressed in high proportions (>50%) of  memory T cells 
from somatically reverted patients, but in fewer (<10%) naive CD4+ T cells, B cells, and NK cells (48). 
Although they had DOCK8+ lymphocytes, clinical improvements in DOCK8-revertant patients were mild, 
with all continuing to have significant disease and some undergoing HSCT (48). This may be because the 
revertant population continues to express an exhausted/senescent phenotype (48), which may compromise 
their response to antigenic stimuli. These data also suggest that DOCK8 is required in most lymphocyte 
populations, including naive T and B cells, to achieve significant clinical improvements. Indeed, the finding 
that the TCR repertoire of  DOCK8-revertant cells is dominated by a few Vβ clonotypes (48) implies that 
a restricted repertoire is not conducive to eliciting robust immune responses in DOCK8-revertant patients. 
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We detected >90% donor chimerism and normal levels of  DOCK8 expression in all transplanted patients. 
This likely explains the dramatic differences in disease outcome in DOCK8-deficient patients who have 
undergone HSCT and those with somatic reversion in only some lymphoid cells.
A caveat of  our study was that we could not analyze pre- and post-HSCT samples from all DOCK8-
deficient patients. However, there were several matched patients. Examination of  these individual patients 
before and after transplant revealed results identical to those from all untransplanted and transplanted 
DOCK8-deficient patients (Supplemental Figure 3). This indicates that our collective results are 
representative of  analysis derived from matched patients.
Comparison of  our results with data from other PID patients who underwent HSCT highlights outcomes 
that are a general consequence of  the transplant process and those that are unique to DOCK8 deficiency. 
The shared characteristic of  reduced frequencies of  memory B cells across both cohorts of  patients was 
consistent with the kinetics of  B cell reconstitution after HSCT in other clinical settings (50). The lack 
of  complete reconstitution of  MAIT and NKT cells after HSCT in both the DOCK8-deficient and the 
other PID patients after HSCT has similarly been reported in patients undergoing HSCT for hematological 
malignancies as late as 12–24 months following transplant (76, 77). This may result from increased 
sensitivity of  MAIT cells to GVHD prophylactic immunosuppressive drugs (77). These observations for 
MAIT and NKT cells in DOCK8 deficiency and the other PIDs examined are reminiscent of  the persistent 
deficiency of  other populations of  innate-type lymphocytes, including NK cells and ILCs, in X-SCID and 
JAK/SCID patients decades after HSCT (78). Thus, an alterative explanation is an inability of  precursors 
of  different innate lymphoid cell populations to adequately seed developmental niches following HSCT 
to enable the reconstitution of  these immune cell lineages. In contrast to these findings, DOCK8-deficient 
patients continued to exhibit greater signs of  T cell exhaustion/senescence after HSCT, with CD8+ T cells 
in transplanted DOCK8-deficient patients remaining skewed toward TEM and TEMRA and being enriched for 
CD57+CD127dim cells.
In conclusion, we detail the numerous adverse effects of  DOCK8 deficiency on the differentiation 
and function of  CD8+ and CD4+ T, MAIT, NK, and B cells that underlie clinical features of  patients 
with DOCK8 mutations. By demonstrating that effective restoration of  key functional defects in adaptive 
immune cells following HSCT corresponds to improved clinical features, we have identified cellular 
mechanisms for the clinical efficacy of  HSCT as a treatment for DOCK8 deficiency. Comparison to 
other PID patients who have also undergone HSCT identified unique and general consequences of  
HSCT in PIDs. Combining our defined readouts of  cellular function with clinical features after HSCT 
may facilitate predicting long-term outcomes for DOCK8-deficient patients undergoing potentially 
curative HSCT. Such an approach has been applied to SCID patients, with several clinical, cellular, 
and functional improvements being established as predictors of  successful outcomes of  HSCT (12, 
79, 80). Collectively, our results underscore the value and importance of  determining the impact of  
monogenic mutations on immune cell function and applying these findings following therapeutic 
interventions in order to ensure optimal patient management and outcomes.
Methods
For antibodies and reagents used in this study, see Supplemental Table 1.
Human samples. PBMCs and plasma were from healthy volunteers (Australian Red Cross) and DOCK8-
deficient patients before and/or after HSCT (Tables 1 and 2). HSCT conditioning is detailed in Table 2. 
PBMCs were available from 7 patients before and after HSCT, and one patient at 2 time points and another 
patient at 3 time points after HSCT. Plasma was analyzed for total and allergen-specific IgE (food or mite 
mix) (26). PBMCs were also collected from patients with recessive mutations in CYBB, STK4, or UNC13D 
or hemizygous CD40LG or SH2D1A mutations who had previously undergone HSCT (Table 3) (62–64).
Phenotyping. Proportions of  CD3+, CD4+ T (CD3+CD4+), CD8+ T (CD3+CD8+), B (CD20+) 
cells; naive (N; CD45RA+CCR7+), central memory (TCM; CD45RA
–CCR7+), effector memory (TEM; 
CD45RA–CCR7–), CD45RA+ revertant memory (TEMRA; CD45RA
+CCR7–) cells; αβ (CD3+TCRαβ+) 
and γδ (CD3+TCRγδ+) T cells; mucosal associated invariant T (MAIT; CD3+TCRVα7.2+CD161+), 
NK (CD3–CD56+), and NKT (CD3+TCRVα24+ Vβ11+) cells; transitional (CD20+CD10+CD27–), naive 
(CD20+CD10–CD27–), memory (CD20+CD10–CD27+), and class-switched (CD20+CD27+ IgD–IgM–) B 
cell subsets were determined by flow cytometry (23, 51, 53, 55, 66). PD-1, CD57, CD27, CD28, and 
CD127 expression was examined on T cells to examine exhaustion (23, 53).
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Analysis of  DOCK8 expression. PBMCs were labeled with CD3, CD4, CD8, CD20, CD56, TCRVα24, 
TCRVβ11, CD161, and Vα7.2 mAbs, fixed, permeabilized, and stained with anti-DOCK8. Alternatively, 
PBMCs were labeled with mouse IgG2 mAbs to CD4, CD8, and CD20; fixed; permeabilized; and stained 
with anti-DOCK8 or isotype control IgG1, then with PE–anti-mouse IgG1.
Lymphocyte isolation and functional analysis. Naive and memory CD4+ T cells were isolated after excluding 
Tregs (CD25hiCD127lo) and sorting CD4+CD45RA+CCR7+ and CD4+CD45RA– cells, respectively (55). CD8+ 
T and naive B cells were isolated as CD8+CD4– and CD20+CD10–CD27–IgG– cells (23, 51), respectively. B cells 
were cultured with CD40L (200 ng/ml), 50 ng/ml IL-21, 1 μg/ml CpG 2006, and/or 0.05% Staphylococcus 
aureus Cowan (SAC) to crosslink the BCR (51, 81). Cells were harvested, stained with Zombie Aqua dye to 
determine viability, and enumerated with Calibrite beads. Ig secretion was determined as described previously 
(51). CD8+ T cells were cultured as described previously (23, 53, 54). CD4+ T cells were cultured under Th0-, 
Th1-, Th2-, or Th17-polarizing conditions, and cytokine production wa determined (26, 55). Cells were 
labeled with CFSE (23, 26); proliferation was determined by assessing CFSE dilution (26).
Statistics. All statistical analysis was performed with GraphPad Prism using unpaired t test with Welch’s 
correction. P values less than 0.05 were considered significant.
Study approval. This study was approved by the Sydney Local Health District RPAH Zone Human 
Research Ethics Committee and Research Governance Office, Royal Prince Alfred Hospital, Camper-
down, New South Wales, Australia (protocol X16-0210/LNR/16/RPAH/257); the South East Sydney 
Local Health District Human Research Ethics Committee, Prince of  Wales/Sydney Children’s Hospital 
(protocol HREC/11/POWH/152); the Royal Children’s Hospital Melbourne Human Research Ethics 
Committee, Parkville, Victoria, Australia (protocol 33146A) and the National Institute of  Allergy and 
Infectious Diseases Institutional Review Board, Bethesda, Maryland, USA (protocol 95-I-0066). Written 
informed consent was obtained from participants or their guardians.
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